NCT06158841: Phase 3: Intravenous (IV) ABBV-383 Monotherapy Versus Standard Therapies Relapsed/Refractory Myeloma
NCT05308654: Phase 1: A Study to Assess activity & AEs in RRMM Receiving Oral ABBV-453 Tablets
NCT05259839: Phase 1: IV Infused ABBV-383 With Anti-Cancer Regimens for Relapsed/Refractory Myeloma
NCT04721002: Evaluate t(11;14) Status & BCL2 Expression in Adult Participants With MM (MEDICI)
NCT04570631: Phase 1: Eftozanermin Alfa (ABBV-621) + Bortezomib and Oral Dexamethasone RRMM
NCT04184050: Phase 1/2: Dose Esc. & Dose Exp. of safety, Tolerability & PK of HPN217 in RRMM
NCT03933735: Phase 1: ABBV-383 (TNB-383B) in Subjects With Relapsed or Refractory Multiple Myeloma
NCT03539744: Phase 3 - A Study of Venetoclax/Dex Compared With Pomalidomide/Dex - t(11;14) +ive RRMM
NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG)
NCT03314181: Phase 2 - Venetoclax, Daratumumab and Dex (+/- Bortezomib) in RRMM Multiple Myeloma
NCT02755597: NCT02755597: Phase 3 - Venetoclax (ABT-199), Bortezomib and Dexamethasone in RRMM
NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in RRMM
NCT02654132 : Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab ( ELOQUENT-3)
NCT01794520: Phase 1/2: Study Evaluating ABT-199 in Participants With Relapsed or Refractory MM
NCT01239797: Phase 3: Lenalidomide and Dexamethasone With or Without Elotuzumab RRMM (ELOQUENT - 2)